Reprogrammed Interchange Llc Sells 449,226 Shares of Vor Biopharma (NYSE:VOR) Stock

Key Points

• Reprogrammed Interchange LLC sold 449,226 shares of Vor Biopharma stock for $898,452, representing a 1.28% decrease in their position as a major shareholder.
• Vor Biopharma stock has traded down 10.4%, currently sitting at $1.80, with a market capitalization of $228.03 million and notable trading activity of over 6 million shares.
• Analysts have a consensus rating of "Moderate Buy" for Vor Biopharma, with a target price of $6.07, indicating positive future expectations despite recent sell-offs.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 449,226 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $2.00, for a total transaction of $898,452.00. Following the transaction, the insider directly owned 34,563,292 shares of the company's stock, valued at $69,126,584. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Monday, September 15th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The shares were sold at an average price of $1.64, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 300,000 shares of Vor Biopharma stock. The shares were sold at an average price of $1.75, for a total transaction of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 284,805 shares of Vor Biopharma stock. The shares were sold at an average price of $1.83, for a total transaction of $521,193.15.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 464,421 shares of Vor Biopharma stock. The shares were sold at an average price of $1.99, for a total transaction of $924,197.79.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 350,000 shares of Vor Biopharma stock. The shares were sold at an average price of $1.82, for a total transaction of $637,000.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The shares were sold at an average price of $1.97, for a total transaction of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 453,016 shares of Vor Biopharma stock. The shares were sold at an average price of $1.93, for a total transaction of $874,320.88.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 554,612 shares of Vor Biopharma stock. The shares were sold at an average price of $2.00, for a total transaction of $1,109,224.00.
• On Thursday, August 28th, Reprogrammed Interchange Llc sold 806,351 shares of Vor Biopharma stock. The shares were sold at an average price of $2.01, for a total transaction of $1,620,765.51.
• On Wednesday, August 27th, Reprogrammed Interchange Llc sold 611,647 shares of Vor Biopharma stock. The shares were sold at an average price of $2.01, for a total transaction of $1,229,410.47.

Vor Biopharma Price Performance

Shares of NYSE VOR traded down $0.14 during mid-day trading on Monday, hitting $1.60. 6,009,423 shares of the company's stock traded hands, compared to its average volume of 7,617,477. The company's 50-day moving average is $2.09 and its two-hundred day moving average is $1.13. The company has a market capitalization of $202.69 million, a P/E ratio of -0.97 and a beta of 2.05. Vor Biopharma Inc. has a 1 year low of $0.13 and a 1 year high of $3.29.

Institutional Trading of Vor Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma in the 1st quarter worth about $100,000. Northern Trust Corp raised its position in Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after purchasing an additional 44,252 shares during the period. Money Concepts Capital Corp raised its position in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares during the period. Trustees of Columbia University in the City of New York purchased a new stake in Vor Biopharma in the 4th quarter worth about $102,000. Finally, Jane Street Group LLC purchased a new stake in Vor Biopharma in the 1st quarter worth about $140,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. HC Wainwright restated a "buy" rating and set a $3.00 target price on shares of Vor Biopharma in a research report on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, Vor Biopharma presently has a consensus rating of "Moderate Buy" and a consensus price target of $6.07.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.